Status:
COMPLETED
Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Lead Sponsor:
University of Kansas
Conditions:
Autosomal Dominant Polycystic Kidney Disease
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Autosomal dominant polycystic kidney disease (ADPKD) is the most common single gene disorder that is potentially fatal. ADPKD is caused by mutations in either of two genes (PKD1, PKD2). Cysts begin to...
Detailed Description
The proposed study will devise a quantitative model to estimate the amount of water an individual would need to ingest in order to lower the 24 h mean urine osmolality to a level below plasma (\~285 m...
Eligibility Criteria
Inclusion
- ADPKD verified by ultrasound, CT or MRI, family history or physical exam
- Normal creatinine clearance, calculated by Cockroft-Gault formulat
- Good general health
- Controlled blood pressure, \< 140/90
- Absence of urinary tract symptoms such as dysuria, hesitancy, diminished flow
Exclusion
- Azotemia
- Uncontrolled hypertension
- Urinary tract symptoms, dysuria, hesitancy, diminished flow, gross hematuria
- Diabetes mellitus, cancer, hematologic disorder
- Unable to follow directions
- Solitary kidney
- History of CHF, liver dysfunction or hyponatremia
- Currently taking diuretics
- Nephrotic range proteinuria (3.5 g/day)
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00759369
Start Date
September 1 2008
End Date
July 1 2009
Last Update
February 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160